Page last updated: 2024-11-06

prethcamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Prethcamide is a synthetic compound that acts as a selective inhibitor of the enzyme monoamine oxidase type A (MAO-A). MAO-A is involved in the breakdown of neurotransmitters such as serotonin, norepinephrine, and dopamine. Prethcamide's inhibition of MAO-A leads to an increase in the levels of these neurotransmitters in the brain, which may have therapeutic effects on conditions such as depression and anxiety. Prethcamide is currently in preclinical development and has shown promising results in animal studies. However, further research is needed to determine its safety and efficacy in humans. Its selective inhibition of MAO-A, along with its potential therapeutic effects on mood disorders, make it an interesting target for further research and development. '

prethcamide: mixture of cropropamide & crotethamide used as respiratory stimulant & analgesic; major descriptor (66-85); on-line search AMINOBUTYRIC ACIDS (66-85); Index Medicus search PRETHCAMIDE (66-85) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71672
SCHEMBL ID2967555
MeSH IDM0262961

Synonyms (10)

Synonym
2-butenamide, n-(1-((dimethylamino)carbonyl)propyl)-n-ethyl-, mixt. with n-(1-((dimethylamino)carbonyl)propyl)-n-propyl-2-butenamide
prethcamide
cropropamide combination with crotethamide
8015-51-8
41a1fcw148 ,
unii-41a1fcw148
SCHEMBL2967555
Q3911267
DTXSID501001000
n-[1-(dimethylamino)-1-oxobutan-2-yl]-n-ethylbut-2-enamide--n-[1-(dimethylamino)-1-oxobutan-2-yl]-n-propylbut-2-enamide (1/1)

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The mean half-life (t1/2 beta, min), the body clearance (Clb, 1/min), the mean absorption rate constant (ka, min1-) and tmax (min) values were, respectively: 43."( Pharmacokinetics of prethcamide following rapid intravenous injection and oral administration in rabbits.
Bryła, P; Szumiło, T,
)
0.45
" Pharmacokinetic parameters for crotethamide and cropropamide after intravenous and oral dosing were estimated by analysis of plasma concentration versus time data."( Pharmacokinetics of intravenous and oral prethcamide in horses.
Ashcraft, SM; Gerken, DF; Sams, RA, 1997
)
0.56

Bioavailability

ExcerptReferenceRelevance
" The mean half-life (t1/2 beta, min), the body clearance (Clb, 1/min), the mean absorption rate constant (ka, min1-) and tmax (min) values were, respectively: 43."( Pharmacokinetics of prethcamide following rapid intravenous injection and oral administration in rabbits.
Bryła, P; Szumiło, T,
)
0.45

Dosage Studied

ExcerptRelevanceReference
" Pharmacokinetic parameters for crotethamide and cropropamide after intravenous and oral dosing were estimated by analysis of plasma concentration versus time data."( Pharmacokinetics of intravenous and oral prethcamide in horses.
Ashcraft, SM; Gerken, DF; Sams, RA, 1997
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (117)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990113 (96.58)18.7374
1990's2 (1.71)18.2507
2000's1 (0.85)29.6817
2010's1 (0.85)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.97

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.97 (24.57)
Research Supply Index4.89 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.97)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (1.52%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other130 (98.48%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]